TVA Sports

NOW 0.10$$

Kane Biotech and the U.S. Army Institute of Surgical Research Sign Cooperative Research and Development Agreement
WINNIPEG, MANITOBA--(Marketwire - Oct. 1, 2012) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms announces that a Cooperative Research and Development Agreement (CRADA) has just been signed with the U.S. Army Institute of Surgical Research (USAISR) in Fort Sam Houston, Texas. This agreement replaces the original agreement that was previously signed with the Walter Reed Army Institute of Research.

The primary objective of this collaboration on "Treatments to Prevent Biofilm Formation for Promoting Wound Healing" is to develop an antibiofilm-antimicrobial wound gel formulation and test the said gel formulation to address the needs of the United States Army Dental and Trauma Research Detachment's (USADTRD) programs and that can be readily translated into clinical testing for improving the outcomes of wounded casualties. The collaboration includes conducting research using wound infections to test the efficacy of the wound gel containing antimicrobial peptide KSL-W and DispersinB® antibiofilm enzyme in killing biofilm-embedded bacteria by disrupting biofilms formed on the wound surface.

The mission of the United States Army Dental and Trauma Research Detachment (USADTRD) is to provide military relevant research and solutions to treat and rehabilitate craniomaxillofacial trauma and prevent infectious disease. The USADTRD's Biofilm Impaired Wound Healing program focuses on providing algorithms to understand biofilm pathophysiology and test agents useful to treat not only dental biofilm (plaque) and combat wounds-associated biofilm infections, but also to provide antimicrobials for the control of dental plaque-associated oral infections.

About Kane Biotech Inc.

Autre petite new.

Kane Biotech Issued New Patent in Japan for DispersinB(R)
WINNIPEG, MANITOBA--(Marketwire - Oct. 16, 2012) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce the issuance of Patent (No.5073169) entitled "Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms" by the Japan patent office. This patent covers the Company's unique DispersinB® biofilm technology.

The patent claims the gene encoding DispersinB® enzyme and also amino acid sequence of the enzyme. In addition, the claims include: (i) a method of producing DispersinB, (ii) pharmaceutical compositions comprising DispersinB® and an antibody or an antibiotic/antimicrobial, (iii) methods of administration, and (iv) applications in medical devices, wound care and oral care.

The issuance of this new DispersinB patent in Japan follows the recent issuance of the Japanese patent for the Company's Aledex® antibiofilm-antimicrobial technology for medical device coatings which was announced in September this year.

"We are very excited to have been granted this Japanese patent that provides additional global protection for DispersinB technology," stated Gord Froehlich, President and Chief Executive Officer of Kane Biotech.

About Kane Biotech Inc.

Toujour in

Ils ont encore sorti plusieurs petites new ce mois ci.

En plus il est super beau a suivre

Il est du pour une petite ride lui

De petit achat d,initiées.


Nov 5/12 Nov 5/12 Madhyastha, Maravanthe Srinivasa Direct Ownership Common Shares 10 - Acquisition in the public market 4,500
Nov 5/12 Nov 2/12 Madhyastha, Maravanthe Srinivasa Direct Ownership Common Shares 10 - Acquisition in the public market 5,500 $0.085

Nov 2/12 Nov 1/12 Madhyastha, Maravanthe Srinivasa Direct Ownership Common Shares 10 - Acquisition in the public market 10,000 $0.085

Nov 1/12 Nov 1/12 Froehlich, Gordon John Direct Ownership Common Shares 10 - Acquisition in the public market 8,000 $0.085

Oct 31/12 Oct 31/12 Froehlich, Gordon John Direct Ownership Common Shares 10 - Acquisition in the public market 10,000 $0.085

Oct 27/12 Oct 26/12 Froehlich, Gordon John Direct Ownership Common Shares 10 - Acquisition in the public market 6,000 $0.090

Aug 31/12 Aug 30/12 Froehlich, Gordon John Direct Ownership Common Shares 10 - Acquisition in the public market 27,000 $0.070

Aug 14/12 Aug 14/12 Hamza, Essam Direct Ownership Common Shares 10 - Acquisition in the public market 50,000 $0.065

Jul 27/12 Jul 27/12 Hamza, Essam Direct Ownership Common Shares 10 - Acquisition in the public market 50,000 $0.070

Si on passe le 0.10$$ on va avoir une belle ride pas grand vendeurs sur level 2

Manque juste un peu de volume et BOUMMMMMMMM

Le volume est en hausse depuis hier....à suivre...

A+
François

'Même un écureuil aveugle peut trouver une noix de temps en temps'

Méchant volume aujourd'hui, plus de 1.6MM....probablement un 'cross-trade' ou quelqu'un qui voulait vraiment, mais vraiment entrer dans le titre...

A+
François

'Même un écureuil aveugle peut trouver une noix de temps en temps'

Wow ! 3% du 'float total' qui change (ou semble) changer de main aujourd'hui...à suivre de près...

A+
François

'Même un écureuil aveugle peut trouver une noix de temps en temps'

Toujours in et meme augmenté ma position

A suivre il est sur le bord de partirrrrrrrrrrr

Le 0.10$$se fait gruger

OUPSSSSSSS déja le 0.11$$

Pas grands vendeurs sur level 2

Plus grand résistance la moindre petite new va le faire exploser

Beau close a 0.11$ sur bon volume

La suite demain

Prise deux

A suivre

In

J,étais absent vendredi en pm quelle surprise de le voir a 0.14$$ ce matin

NOW 0.15$$ 90%% en moins d,un mois

Encore une journée avec un volume au-dessus du million, pour une cie qui a seulement 60MM (environ) d'actions en circulation c'est un volume d'échange très important.

De plus, les initiés ont acheté passablement au cours des derniers mois....à suivre.

Pour ceux que cela intéresses, lien vers site web;
http://www.kanebiotech.com/

A+
François

'Même un écureuil aveugle peut trouver une noix de temps en temps'

A suivre il veut partirrrrrrrrrrrr

IN

Toujour a la hausse direction 0.20$$